EXUMA Biotech is developing CAR-T cell therapies specifically for solid tumors using its rPOC Subcutaneous platform, which eliminates the need for lymphodepleting chemotherapy and allows for administration outside of tertiary care settings. This approach addresses the limitations of traditional cell therapies by enhancing efficacy and safety while improving patient access to innovative treatments.
Funding
$122M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional CAR-T cell therapies for solid tumors face limitations in efficacy and safety, often requiring lymphodepleting chemotherapy and administration within specialized tertiary care settings. This restricts patient access and increases the complexity and cost of treatment.
Solution
EXUMA Biotech is developing CAR-T cell therapies for solid tumors using its rPOC Subcutaneous (SC) platform, designed to enhance both efficacy and safety. The rPOC SC platform facilitates CAR-T cell production within a dedicated synthetic lymph node, potentially eliminating the need for lymphodepleting chemotherapy. This approach allows for CAR-T cell therapy administration in settings outside of tertiary care, improving patient access to these advanced treatments. EXUMA is also advancing its GCAR platform to enable in vivo CAR-T therapy.
Target Audience
The primary target audience includes patients with solid tumors who may benefit from CAR-T cell therapy, as well as healthcare providers and institutions seeking to expand access to cell and gene therapies outside of traditional tertiary care settings.
Features
- rPOC Subcutaneous (SC) platform: A synthetic lymph node approach designed to optimize CAR-T cell production and reduce the need for lymphodepleting chemotherapy.
- GCAR platform: Enables in vivo CAR-T cell therapy by reprogramming the patient's own lymph nodes.
- CD3-Targeted Lentivector: Selectively targets and loads lymphocytes ex vivo or in vivo for transduction and expansion, reducing manufacturing complexity.
- FITNESS DRIVER transgene: Encodes a semi-synthetic protein to enhance effector cell stemness, proliferation, persistence, and cytotoxicity.
- Tumor Metabolism Regulated (TMR) CARs: Expands the range of targetable antigens beyond those typically found in blood cancers.
- Synthetic CAR Ligands (SCL): Enables expansion and persistence of CAR-T cells through the administration of an off-the-shelf mRNA encoding a CAR activating ligand, providing physicians with greater control over pharmacokinetics.